Clinical trial
Visudyne® in Occult (VIO)
NCT00121407 · QLT Inc., Industry · Completed
Key facts
| NCT number | NCT00121407 |
|---|---|
| Title | Visudyne® in Occult (VIO) |
| Official title | A Randomized, Placebo-Controlled, Double-Masked, Multicenter, Phase III Study of the Effect of Visudyne Therapy in Occult With No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne in Occult (VIO) |
| Lead sponsor | QLT Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Visudyne for injection |
| Enrollment | 364 |
| Start date | Mar 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Jul 21, 2005 |
| Last update posted | Jul 21, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: